A systematic review and economic model of the effectiveness and ...

140. Hill P, Taylor E. An auditable protocol for treating
attention deficit/hyperactivity disorder. Arch Dis
Child 2001;84:404–9.
141. Netten A, Curtis L. Unit costs of health and social
care. Canterbury: Personal Social Services Research
Unit (PSSRU), University of Kent; 2002. URL:
www.pssru.ac.uk
142. Biederman J, Heiligenstein JH, Faries DE, Galil N,
Dittmann R, Emslie GJ, et al. Efficacy of
atomoxetine versus placebo in school-age girls
with attention-deficit/hyperactivity disorder.
Pediatrics 2002;110:e75.
143. Efron D, Jarman F, Barker M. Side effects of
methylphenidate and dexamphetamine in
children with attention deficit hyperactivity
disorder: a double-blind, crossover trial. Pediatrics
1997;100:662–6.
144. Weiss M, Tannock R, Kratochvil C, Dunn D,
Velez-Boras J, Thomason C, et al. Placebocontrolled
study of once-daily atomoxetine in the
school setting. Eur Neuropsychopharmacol 2003;13
(suppl 4):S456.
145. Secnik K, Cottrell S, Matza LS, Edgell E,
Aristides M, Tilden D, et al. Assessment of health
state utilities for attention-deficit/hyperactivity
disorder in children using parent-based standard
gamble scores. In 9th Annual International Meeting
of the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR), 16–19 May 2004,
Arlington, VA.
146. Briggs AH. Handling uncertainty in costeffectiveness
models. Pharmacoeconomics 2000;
17:479–500.
147. Spiegelhalter DJ, Thomas A, Best NG, Gilks WR.
BUGS: Bayesian inference using Gibbs sampling,
version 0.5, (version ii). Cambridge: MRC
Biostatistics Unit; 1996.
148. Hill JC, Schoener EP. Age-dependent decline of
attention deficit hyperactivity disorder. Am J
Psychiatry 1996;153:1143–6.
149. Sharp WS, Walter JM, Marsh WL, Ritchie GF,
Hamburger SD, Castellanos FX. ADHD in girls:
clinical comparability of a research sample. J Am
Acad Child Adolesc Psychiatry 1999;38:40–7.
150. Higgins JPT, Whitehead A. Borrowing strength
from external trials in a meta-analysis. Stat Med
1996;15:2733–49.
151. Ades AE, Cliffe S. Markov Chain Monte Carlo
estimation of a multi-parameter decision model:
consistency of evidence and the accurate
assessment of uncertainty. Med Decis Making
2002;22:359–71.
152. Claxton AJ, Cramer J, Pierce C. A systematic
review of the associations between dose regimens
and medication compliance. Clin Ther
2001;23:1296–310.
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 23
153. Netten A, Curtis L. Unit costs of health and social
care. Canterbury: Personal Social Services Research
Unit (PSSRU), University of Kent; 2004. URL:
www.pssru.ac.uk
154. Celltech Pharmaceuticals Limited. Appraisal of
drugs used in attention deficit hyperactivity disorder.
A submission to the National Institute for Clinical
Excellence. Slough: Celltech Pharmaceuticals; 2004.
155. Janssen-Cilag. For health technology appraisal:
methylphenidate, atomoxetine and dexamphetamine for
attention-deficit/hyperactivity disorder in children and
adolescents, including review of existing guidance
number 13. A submission to the National Institute
for Clinical Excellence. High Wycombe: Janssen-
Cilag Limited; 2004.
156. Eli Lilly. Atomoxetine for the treatment of ADHD. A
submission to the National Institute for Clinical
Excellence. Basingstoke: Eli Lilly and Company
Limited; 2004.
157. National Institute for Health and Clinical
Excellence (NICE). National Institute for Clinical
Excellence methodological guidance: economic
evaluations. London: NICE; 2004.
158. Biederman J, Mick E, Faraone S. Age-dependent
decline of symptoms of attention deficit
hyperactivity disorder: impact of remission
definition and symptom type. Am J Psychiatry
2000;157:816–18.
159. Moher D, Schulz KF, Altman DG. The CONSORT
statement: revised recommendations for
improving the quality of reports of parallel-group
randomised trials. Lancet 2001;357:1191–4.
160. Aggarwal A, Lillystone D. A follow-up pilot study
of objective measures in children with attention
deficit hyperactivity disorder. J Paediatr Child
Health 2000;36:134–8.
161. Akhondzadeh S, Tavakolian R, Davari-Ashtiani R,
Arabgol F, Amini H. Selegiline in the treatment of
attention deficit hyperactivity disorder in children:
a double blind and randomized trial. Prog
Neuropsychopharmacol Biol Psychiatry 2003;27:841–5.
162. Akhondzadeh S, Mohammadi MR, Khademi M.
Zinc sulfate as an adjunct to methylphenidate for
the treatment of attention deficit hyperactivity
disorder in children: a double blind and
randomized trial [ISRCTN64132371]. BMC
Psychiatry 2004;4:9.
163. Allen AJ, Spencer TJ, Heiligenstein JH, Faries DE,
Kelsey DK, Laws HF, et al. Safety and efficacy of
tomoxetine for ADHD in two double-blind,
placebo-controlled trials. Biol Psychiatry
2001;49:325–35.
164. Allen AJ, Michelson D, Harder Donald R,
Trapp NJ, Kelsey DK. Efficacy of atomoxetine in
children and adolescents with ADHD. In 155th
Annual Meeting of the American Psychiatric Association,
18–23 May 2002, Philadelphia, PA.
139